Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLL

Commentary
Video

Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.

Efficacy and safety data from the phase 1/2 TRANSCEND CLL 004 study (NCT03331198) presented during the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition appear tosupport lisocabtagene maraleucel (liso-cel; Breyanzi) as a next-line therapy for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to Tatyana Feldman, MD, in an interview with CancerNetwork®.1

Feldman, an attending physician at John Theurer Cancer Center at Hackensack Meridian Health, highlighted data related to responses and survival in both the overall study population (n = 88) and a primary efficacy analysis set including those with disease progression following prior therapy with Bruton tyrosine kinase (BTK) inhibitors and venetoclax (Venclexta; n = 50). Based on these findings, she anticipates that liso-cel will hopefully receive regulatory approval as a treatment option in CLL.

The FDA previously granted priority review to liso-cel as a treatment for relapsed/refractory CLL or small lymphocytic lymphoma in November 2023 based on findings from the TRANSCEND CLL 004 study.2

Transcript:

We have an overall response rate [in the overall population] which sits at [48%] with a complete response rate—which was a primary end point—at [19%]. And what’s very important is that undetectable MRD in the blood for both cohorts was [66%], which is a very high number. As this analysis showed, that translates into duration of response; [these are] very meaningful responses. The duration of complete response is not reached, and duration of partial response is also quite long. We have 24.0 months for the total cohort and [12.4] months for the double-resistant cohort. Time to next therapy, which was a post-hoc analysis, was [18.4] months and [12.4] months, respectively.

These are very reputable numbers for these patient populations.

Overall survival was not reached in patients who achieved a response and [10.7] months for non-responders. From a standpoint of toxicity, there are no novel signals. Cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS] incidences were 85% and 45%, respectively. However, most of it was grade 1/2 and easily manageable. [Liso-cel] is hopefully going to be approved intervention soon [for] our armamentarium for [patients with] CLL.

This analysis is confirming the duration of the response [of liso-cel]. We have such a long duration of complete responses—which was not reached—as well as a very reputable duration of partial response of [18.4] months. This is a very important [treatment] that should be adopted by the community as a next-line therapy. That’s my opinion, particularly for the patients who progress after BTK inhibitors and BCL2 inhibitors.

References

  1. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. Blood. 2023;142(suppl 1):abstract 330. doi:10.1182/blood-2023-179529
  2. U.S. Food and Drug Administration accepts for priority review Bristol Myers Squibb’s application for Breyanzi (lisocabtagene maraleucel) for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). News release. Bristol Myers Squibb. November 9, 2023. Accessed December 14, 2023. https://shorturl.at/pJMS6
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content